Alder BioPharmaceuticals stores rockets in large quantities after $ 1.95 billion buyout
[ad_1] Shares of Alder BioPharmaceuticals Inc. ALDR, + 83.90% Monday, after the developer of the migraine treatment eptinezumab had agreed to be bought by the Danish company H. Lundbeck A / S HLUYY, -0.89% MON, -2.00% in a transaction valued at $ 1.95 billion. The trading volume was already 4.6 million shares higher one hour … Read more